Objective:

To evaluate mitragynine as a potential treatment for opioid use disorder through a phase I clinical trial.

Approach:

Key Findings:

• Mitragynine is the primary psychoactive compound in kratom, which has gained interest as a treatment for opioid use disorder.
• Preclinical studies indicated that mitragynine did not raise significant safety concerns in animal models.
• The IND application enables the transition from preclinical to human studies.

Interpretation:

The IND marks a significant step towards exploring new treatment options for opioid use disorder.

Limitations:

• Mitragynine has not yet been studied in humans prior to this trial.

Conclusion:

The trial is part of the NIH HEAL Initiative aimed at addressing opioid addiction.

Sources:

• NIH Official Announcement
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.